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 Background: Increasing immunosuppressant utilization and expenditure is a worldwide challenge as more people success-
fully live with transplanted organs. Our aims were to characterize utilization of mycophenolate, tacrolimus, cy-
closporin, sirolimus, and everolimus in Australian transplant recipients from 2007 to 2013; to identify specific 
patterns of usage; and to compare Australian utilization with Norwegian, Danish, Swedish, and the Netherlands 
use.
 Material/Methods: Australian utilization and expenditure data were captured through national Pharmaceutical Benefits Scheme 
and Highly Specialized Drug administrative databases. Norwegian, Danish, Swedish, and the Netherlands uti-
lization were retrieved from their healthcare databases. Utilization was compared as defined daily dose per 
1000 population per day (DDD/1000 population/day). Data on kidney transplant recipients, the predominant 
patient group prescribed these medicines, were obtained from international transplant registries.
 Results: From 2007–2013 Australian utilization of mycophenolic acid, tacrolimus and everolimus increased 2.7-fold, 2.2-
fold, and 2.3-fold, respectively. Use of cyclosporin and sirolimus decreased 20% and 30%, respectively. Australian 
utilization was significantly lower than European utilization (2013) but was increasing at a faster rate. Total 
Australian expenditure increased approximately AUD$30 million over the study period to almost AUD$100 mil-
lion in 2013. Kidney transplantation rates increased across each country over this time, with Australia having 
the lowest rate.
 Conclusions: Immunosuppressant usage and subsequent expenditure are rising in Australia and Northern Europe. With in-
creased numbers of people living with transplants, and the observed growth potential predicted from Northern 
European data, this class of medicines can be expected to continue consuming an increasing share of Australian 
pharmaceutical expenditure into the future.
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Background
Transplant recipients require life-long immunosuppressant ther-
apy to treat and prevent rejection events that would other-
wise jeopardise the performance and longevity of their newly 
acquired graft [1,2]. Immunosuppressant medicines are used 
in 3 treatment stages; induction, as maintenance therapy and 
for acute treatment of organ rejection [3]. Community costs 
are highest for long-term maintenance immunosuppressant 
therapy, following hospital discharge after transplantation [4]. 
The kidney is the most common solid organ transplanted; in 
Australia over 9000 people currently live with a functioning 
kidney allograft, with over 800 further kidney transplant oper-
ations per annum [5]. Increasing rates of utilization and expen-
diture on immunosuppressants present a worldwide challenge.
Advances in maintenance immunosuppression have led to re-
ductions in acute rejection rates and improvements to short-
term patient survival over the past 2 decades [6,7]. In contrast, 
the evaluation of long-term graft survival has been difficult to 
interpret with contradictory data being reported [8–10]. The 
goal of maintenance immunosuppressant therapy is to max-
imize long-term allograft survival while minimizing acute re-
jection, drug toxicity and over-immunosuppression leading to 
infections and certain types of cancer [11]. The immunosup-
pressant agents, mycophenolic acid, tacrolimus, cyclosporin, 
sirolimus and everolimus, used in various combinations, often 
with corticosteroids (prednisone or prednisolone), form the ba-
sis of contemporary maintenance therapy for transplant re-
cipients [11,12]. Each of these agents receives public subsi-
dy in Australia through the national Pharmaceutical Benefits 
Scheme (PBS) for the prevention and/or treatment of renal 
allograft rejection following transplantation, while some are 
also subsidized for other less commonly transplanted organs 
or for the management of certain autoimmune conditions [13]. 
Dispensing of these medicines is also publically subsidized 
in Northern European countries such as Norway, Denmark, 
Sweden, and the Netherlands. With reasonably similar eco-
nomic conditions, health care systems and scope of prescrib-
ing, these 5 countries prove good comparison data for inter-
national pharmacoepidemiologic research.
To date, there has only been a single paper investigating the 
epidemiology and economics associated with usage of main-
tenance immunosuppression in Australia [14]. This 2009 
study compared mycophenolic acid utilization in Australia and 
Northern Europe to develop a rational baseline for projections 
of future utilization and costs [14].
The aim of the present study is to examine the utilization 
of mycophenolic acid, tacrolimus, cyclosporin, sirolimus and 
everolimus in Australian transplant recipients, and to compare 
and contrast Australian data with the publically subsidized 
utilization data from Norwegian, Swedish, Danish, and the 
Netherlands.
Material and Methods
Data source
Australian records relating to PBS dispensing and expenditure 
were collected from the administrative database, Medicare 
Australia Item Statistics [15]. Specific item codes associat-
ed with the various forms, strengths and types of subsidy for 
each studied drug (Appendix 1) were entered into the data-
base and a utilization report generated providing the number 
and cost of PBS prescriptions dispensed per month between 
2007 and 2013 [13]. Due to division in state and federal gov-
ernment responsibilities in health care provision and changes 
in funding models over the study period, all hospital utiliza-
tion and expenditure information prior to 2014 were not fully 
characterized using PBS item statistics alone [13,15]. To cap-
ture hospital-specific utilization and expenditure, the highly 
specialized drug (HSD) national expenditure reports (public and 
private hospitals) [16,17] were used. Mid-year data on popu-
lation in Australia were obtained from the Australian Bureau 
of Statistics [18]. Data on utilization for each immunosuppres-
sant in Norway, Denmark, Sweden and the Netherlands were 
obtained from their respective healthcare databases [19–22]. 
Data in these archives were available as either daily defined 
dose (DDD) or DDD/1000 population/day [23]. Mid-year data 
on population size in each of these countries were obtained 
from their respective government databases [24–27]. Australian, 
Norwegian, Danish, and the Netherlands immunosuppressant 
utilization data were obtained from both the community and 
hospital settings. Swedish data were only available for com-
munity pharmacy dispensing.
Information relating to all allograft transplant operations per-
formed per year, number of renal transplants currently func-
tional in the community and rates of renal transplantation per 
million population was gathered from Australian Transplant 
Registries [5,28,29] while international renal transplantation 
figures were obtained from the International Registry of Organ 
Donation and Transplantation (IRODaT) maintained on behalf 
of Scanditransplant and Eurotransplant [30].
Data analysis
Australian PBS and HSD data relating to the utilization of my-
cophenolic acid, tacrolimus, cyclosporin, sirolimus and evero-
limus were collated as number of prescriptions dispensed per 
month from 2007 to 2013. To allow international comparison 
and analysis these data were converted to DDDs. The DDD 
(2014) for mycophenolate mofetil was 2000mg, tacrolimus 5 mg, 
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cyclosporin 250 mg, sirolimus 3 mg and everolimus 1.5 mg [23]. 
The DDD for mycophenolate was listed as the mofetil salt and 
to adjust this to enable aggregation of all different salt forms 
as mycophenolic acid this was multiplied by 0.739 (DDD for 
mycophenolic acid 1478mg). DDD for all formulations for each 
drug were then added together. DDD/1000 population/day was 
calculated for each year. In short, the number of dispensings 
was multiplied by the pack size and strength of each individ-
ual dosage form (tablet, capsule and suspension) to obtain to-
tal milligrams per year. Milligram per year were then divided 
by the DDD for each immunosuppressant and finally divided 
by the Australian population, in thousands, and multiplied by 
the number of days in each respective year. A similar process 
was applied to HSD reporting where information on the num-
ber of dispensings per quarter for each specific PBS item code 
was available between 2007 and 2013. These were multiplied 
by pack size and strength, divided by appropriate DDD and fi-
nally adjusted for population size and days in a year. In both 
PBS and HSD databases, data relating to the use of mycophe-
nolate sodium for use in lupus nephritis, recognized by sepa-
rate item numbers, were excluded to enable transplantation-
specific utilization to be calculated.
To calculate the total DDD/1000 population/day for each im-
munosuppressant in Australia, both PBS and HSD sources were 
summed. Because of the ongoing changes to hospital and pub-
lic subsidy over the study period, the PBS utilization data were 
corrected to exclude all hospital HSD-related PBS item codes, 
as these were already captured by HSD reporting. This ensured 
no “double counting” in the overall results. Total expenditure 
was calculated similarly to utilization. PBS and HSD reporting 
were summated, again removing HSD-related PBS item codes 
from PBS item statistic reports to avoid “double counting”.
Sensitivity analysis was performed for 2 possible limitations:
a.  Including Australian data relating to mycophenolate sodi-
um dispensing in lupus nephritis to estimate any impact if 
this indication were included in the international data.
b.  Using a DDD of 2g for mycophenolic acid formulations to 
study the influence this may have had on the comparisons 
to international use, as international data may not have ac-
counted for the mofetil salt adjustment of 0.739.
Differences in utilization between the Northern European coun-
tries and Australia were evaluated with descriptive analyses. Chi 
squared analyses were performed, testing the null hypothesis 
that there was no difference in utilization between Australia 
and each of the other countries (2013). Statistical significance 
was p<0.05 (VassarStats online clinical research Chi Square 
calculator [31]). Linear regression analysis (Microsoft Office: 
Excel®) was used to calculate the rate of change over time in 
utilization of the 5 immunosuppressant agents combined in 
Australia and the Northern European countries.
Results
Utilization of all formulations of mycophenolic acid, tacrolim-
us, cyclosporin, sirolimus and everolimus in Australia between 
2007 and 2013 is shown in Figure 1. Mycophenolic acid showed 
a 175% or 2.7-fold increase from 0.095 DDD/1000 popula-
tion/day in 2007 to 0.260 DDD/1000 population/day in 2013. 
Tacrolimus increased from 0.113 DDD/1000 population/day in 
2007 to 0.248 DDD/1000 population/day in 2013, a 2.2-fold or 
120% increase in utilization. Cyclosporin utilization decreased 
by approximately 20% from 0.169 DDD/1000 population/day 
in 2007 to 0.135 DDD/1000 population/day in 2013. Sirolimus 
utilization similarly decreased by 30% from 0.025 DDD/1000 
population/day in 2007 to 0.018 DDD/1000 population/day in 
2013. Lastly, everolimus utilization increased by 2.3-fold from 
0.018 DDD/1000 population/day in 2007 to 0.041 DDD/1000 
population/day in 2013.
When considering the specific formulations of mycophenolic 
acid and tacrolimus individually, utilization of enteric-coated 
mycophenolate sodium increased from approximately 18% of 
total mycophenolic acid consumption in 2007 to 27% of total 
mycophenolic acid consumption in 2013, taking market share 
from the mycophenolate mofetil formulation. Similarly usage 
of extended-release tacrolimus, first dispensed in December 
2010, has grown continually such that it now accounts for 10% 
of the total tacrolimus consumption in 2013.
Dispensing and provision of these 5 medicines in Australia can 
be through community pharmacies or public and private hos-
pitals. Between 2007 and 2013 approximately 25% of total 
supply was via community pharmacies, through general pub-
lic subsidization, while 70% and 5% was via public and private 
hospitals, respectively, through the HSD scheme.
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Figure 1.  Utilization of mycophenolic acid ( ), tacrolimus ( ), 
cyclosporin ( ), sirolimus ( ) and everolimus ( ) in 
Australia between 2007 and 2013.
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Figure 2 displays the comparisons between Australia, Norway, 
Denmark, Sweden and the Netherlands for each of the 5 im-
munosuppressants. Patterns of utilization are similar across 
each of the 5 nations (i.e., rising usage of mycophenolic acid, 
tacrolimus and everolimus, falling usage of cyclosporin and si-
rolimus) while Norwegian utilization was consistently higher 
than the other 4 countries. In 2013, utilization of mycophe-
nolate, tacrolimus and cyclosporin was significantly higher for 
each European country compared to Australia (Chi-squared 
analyses; p<0.001 for each medication). While sirolimus and 
everolimus use was lower in Australia compared to each 
European country, these differences were not statistically sig-
nificant. Australian utilization (all 5 medications combined) was 
found to be growing faster than Denmark, at similar rates to 
Sweden and the Netherlands and slower than Norway (0.009, 
0.005, 0.009, 0.009 and 0.01 DDD/1000 population/day per 
year, respectively). Overall Australian utilization was growing 
slightly faster than total Northern European utilization (0.009 
verses 0.007 DDD/1000 population/day per year).
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Figure 2.  International comparison of utilization for (A) mycophenolic acid, (B) tacrolimus, (C) cyclosporin, (D) sirolimus, and (E) 
everolimus between Norway ( ), Denmark ( ), Sweden ( ), The Netherlands ( ), and Australia ( ).
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Australian public subsidy for the maintenance immunosup-
pressants is represented in Figure 3. Combining total commu-
nity and hospital expenditure the immunosuppressant with 
the highest cost to the Australian government was tacrolim-
us at AUD$40 million in 2013. Second was mycophenolic acid 
with a financial outlay of AUD$30 million in 2013. Third was 
everolimus with government reimbursement increasing from 
AUD$3 million in 2007 to just over AUD$9 million in 2013. 
These represent increases of 110%, 30% and 180%, respec-
tively. Conversely, cyclosporin expenditure decreased 25% from 
AUD$23 million in 2007 to AUD$17 million in 2013. Sirolimus 
expenditure decreased by AUD$1 million over the study pe-
riod (20% decrease). Dispensing and subsidization of these 5 
medicines in Australia can be through community pharmacies 
or public and private hospitals. Community pharmacies ac-
counted for approximately 25% of subsidized costs from 2007 
to 2013 whereas subsidy through the HSD scheme to public 
and private hospitals accounted for 70% and 5%, respectively, 
between 2007 and 2013. Overall, public funding of the 5 stud-
ied immunosuppressants has increased from AUD$70 million in 
2007 to almost AUD$100 million in 2013, a 1.4-fold increase.
Kidney transplantation accounted for 61% of all solid organs 
transplanted in Australia in 2012 while liver, lung, heart and 
pancreas transplantation contributed 19%, 11%, 6% and 2%, 
respectively [5,28,29]. Figure 4 shows the number of renal 
transplant operations per million population and the number 
of people living with a functioning renal allograft between 
1991 and 2012 in Australia. The rates of both have continual-
ly increased over this period.
Figure 5 displays the number of new kidney transplants 
conducted in Australia, Denmark, Norway, Sweden and the 
Netherlands per million population 2007–2012. Kidney trans-
plant rates increased across all countries, however Norway and 
the Netherlands had more transplants per million population 
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Figure 3.  Total cost of mycophenolic acid ( ), tacrolimus ( ), 
cyclosporin ( ), sirolimus ( ), and everolimus ( ) to 
the Australian government through community and 
hospital subsidization.
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Figure 5.  Number of new renal transplants per million 
population per year in Denmark ( ), Norway ( ), 
Sweden ( ), the Netherlands ( ), and Australia ( ) 
between 2000 and 2012.
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Figure 4.  (A) Number of renal transplant operations in Australia per million population 1991–2012 and (B) number of functioning renal 
allografts in the Australian community 1991–2012.
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with 60 and 57.5, respectively, compared to Australia, Denmark 
and Sweden with 36.7, 37.6 and 41.8, respectively.
Sensitivity analyses showed inclusion of PBS item codes pertain-
ing to the use of mycophenolate in lupus nephritis (Appendix 1) 
increased overall Australian utilization figures by 2% where-
as using the DDD for the mofetil salt of mycophenolate, rath-
er than the corrected DDD for mycophenolic acid contribut-
ed a 9% drop.
Discussion
This study for the first time documents the increasing use of 
maintenance immunosuppressive medications, contrasting dif-
ferent countries which have publicly funded subsidy for these 
medications. Immunosuppressant usage and subsequent expen-
diture are rising in Australia and Northern Europe. The number 
of transplant operations performed each year and the number 
of people living with a functioning renal allograft in the com-
munity is rising. With the current ageing population [32,33] and 
increasing rates of hypertension and type II diabetes [32]; new 
techniques such as ABO incompatible live donor transplanta-
tion and HLA desensitization providing avenues to increase or-
gan availability [34,35]; and improvements in post-transplant 
care it is expected that the number of people requiring a trans-
plant and those living with a functional allograft will continue 
increasing into the future. This will have future implications 
for the pharmaceutical budgets of these countries.
All the Northern European countries in this study had higher 
utilization of the maintenance immunosuppressant medica-
tions than Australia. Australia has an opt-in system for organ 
donation requiring citizens to nominate themselves as organ 
donors [34]. Internationally, The Netherlands and Denmark have 
a similar opt-in system [30] but both still have higher rates of 
transplantation than Australia [30]. Norway and Sweden have 
an opt-out system for organ donation and everybody is con-
sidered as a potential organ donor unless they specify other-
wise [30]. These differing policies may be one of the underly-
ing factors contributing to the larger number of transplants per 
head of population in these countries compared to Australia, 
and hence higher immunosuppressant use. The specific pat-
terns of utilization in Australia and Northern Europe show 
that mycophenolic acid, tacrolimus and everolimus utilization 
had an increasing and steady uptake. This practice is support-
ed by literature evidence that a mycophenolic acid/tacrolimus 
regimen offers patients an increased length and quality of life 
when compared to the previously common azathioprine/cyclo-
sporine regimen [11]. As tacrolimus can cause nephrotoxicity 
and subsequent rejection, everolimus substitution has shown 
promise as an alternative for the long-term management of 
rejection combined with mycophenolic acid [36]. Everolimus 
substitution is considered most clinically appropriate between 
12 and 72 months post-transplant [37–40]. This evidence aligns 
well with the observed results and provides insight into the 
evolving practice of prescribers being shaped by the current 
literature. Similarly, cyclosporin and sirolimus utilization is de-
creasing, also supported by current evidence. Tacrolimus has 
been identified as a clinically and pharmacoeconomically su-
perior calcineurin inhibitor thus a majority of new transplant 
recipients should receive tacrolimus [41]. Nevertheless there 
are no data to suggest that switching from cyclosporin to ta-
crolimus after stabilization has benefits on long-term outcomes 
so patients already stabilized on cyclosporin generally remain 
on it [42–44]. This is consistent with utilization patterns seen 
in this study, with cyclosporin utilization decreasing gradual-
ly over time, not dropping off completely. Sirolimus appears 
to be in a similar situation as everolimus use has been shown 
to be clinically non-inferior with a more tolerable side effect 
profile and it appears to be the preferred mammalian target 
of rapamycin inhibitor (mTOR) [37].
Australian utilization was significantly lower for mycopheno-
late, tacrolimus, and cyclosporin compared to the 4 European 
nations (P<0.001). Linear regression, investigating changes 
over time, showed Australian utilization of these 5 medications 
growing at a slightly faster rate than total Northern European 
utilization. Using Northern European utilization as a projec-
tion for growth, it is postulated that Australia is lagging by 
roughly 5 years, probably due to lower transplant rates [30,45]; 
i.e., Australian utilization in 2013 is comparable to Northern 
European utilization in around 2008. Australia has had many 
public campaigns to try to increase organ donation [46]. With 
the potential for growth, Australia could bridge the gap with 
Northern Europe in future years, and it is important that it is 
realized that entails an increase in overall government expen-
diture probably in line with that experienced in recent years 
in Northern European countries.
Australian government expenditure on maintenance immuno-
suppressants has already climbed rapidly to almost AUD$100 
million in 2013. Similar to utilization, government expenditure 
on mycophenolic acid, tacrolimus and everolimus increased 
over the study period. The opposite was recorded for cyclo-
sporin and sirolimus. Several initiatives recently enacted by 
the Australian government, as well as cheaper generic avail-
ability of pharmaceuticals after patent expiry, have introduced 
cost-savings measures and these introduce uncertainty about 
future pricing structures and PBS expenditures. However, by 
considering the increasing number of kidney transplant oper-
ations, functioning kidney transplants in the community and 
potential for widening of the subsidized indications, particu-
larly for mycophenolate [47–49], tacrolimus [50] and everoli-
mus [51–53], immunosuppressant expenditure will continue 
to rise into the future. It is not likely that generic formulations 
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will decrease costs by the amount needed to offset increased 
utilization. It is also important to consider the wider scope of 
health expenditure, not just the government outlay on pre-
scription medicines. Tacrolimus has been demonstrated to be 
a cost-effective option compared to cyclosporin and although 
a more expensive drug in direct costs, indirect cost-savings 
such as reduced hospital stay, longer graft functioning and im-
proved patient quality of life provide benefits [54–56]. Similarly, 
mTOR introduction to the immunosuppressive regime through 
substitution or minimization strategies, although expensive, 
has been estimated to provide a cost-saving role to the over-
all treatment of these patients [36]. It is through pharmaco-
economic analysis the true price of these medicines can be 
understood and displayed in a holistic manner not just with a 
focus on drug acquisition costs [57].
This study did not include other therapies used in the manage-
ment of rejection in renal transplant patients including azathio-
prine, corticosteroids and the biological monoclonal antibodies. 
Azathioprine has now been largely replaced by mycopheno-
lic acid in maintenance regimens and is mainly used for indi-
cations other than rejection prevention [5]. Similarly usage of 
oral corticosteroids (prednis(ol)one) in transplant recipients 
specifically cannot be identified in the PBS database as these 
agents have numerous subsidized indications, all sharing the 
same PBS item code, and cost of these medicines falls below 
the PBS co-payment. Biological monoclonal antibodies are very 
costly treatments sometimes used for induction therapy and 
the treatment of acute rejection. These agents are not includ-
ed in long-term maintenance immunosuppressant regimens 
and thus were not included.
The data relate primarily to kidney transplantation, although 
use of immunosuppressants in other transplant groups was 
included to a lesser extent. Kidney transplantation accounted 
for 61% of all the solid organ transplants in Australia in 2012. 
Mycophenolate is subsidized by the PBS for the use in car-
diac and renal transplantation, tacrolimus for all transplants, 
cyclosporin for all transplants, sirolimus for cardiac and renal 
and everolimus for only renal (Appendix 1). The next highest 
transplant group after renal transplant recipients was liver re-
cipients (19% in 2012), but only tacrolimus and cyclosporin re-
ceive subsidy for this indication.
The Australian PBS administrative database primarily docu-
ments dispensing of publicly subsidized medicines for the pur-
poses of reimbursement and expenditure analysis. This provides 
several limitations for research including the assumption that 
each recorded dispensing was the maximum PBS subsidized 
quantity. It was also assumed that all use of these medicines 
was publically subsidized. Private prescription use however is 
likely to be vanishingly small due to the extremely high prices 
of these medicines and the ready accessibility of public subsi-
dy for all Australian residents. Transplant recipients requiring 
rejection prophylaxis fulfil the subsidy restrictions to receive 
these medicines for a low price.
Sensitivity analyses were conducted to consider the potential 
impact if mycophenolic acid data pertaining to lupus nephritis 
use were included in Northern European data (whereas they 
are separated in Australian data). Inclusion of this informa-
tion together with the data for transplantation only contribut-
ed another 2% to the overall mycophenolic acid utilization in 
Australia, therefore was not likely to make a major difference if 
this use was included in Northern Europe. This study assumed 
that international reporting of mycophenolic acid DDDs and 
DDD/1000 population/day incorporated the mofetil salt cor-
rection factor of 0.739. As it is difficult to ascertain whether 
these databases accounted for this correction or not, further 
sensitivity analyses were conducted to assess the impact this 
would have on results. Sensitivity analyses show that by us-
ing the DDD for mycophenolate of 2000mg instead of 1478mg, 
even the 9% higher apparent utilization which would have re-
sulted would not have been sufficient to explain the difference 
between Australian and Northern European usage.
Conclusions
There is an increasingly large number of Australians receiv-
ing kidney transplant for which they are required to take vari-
ous combinations of mycophenolic acid, tacrolimus, cyclospo-
rin, sirolimus, and everolimus for the remainder of their lives. 
Because of this, immunosuppressant utilization and expendi-
ture is rising in Australia. Internationally, this study found sig-
nificant differences between the utilization of the 5 medicines 
in Australia and Northern Europe. Trends in utilization were con-
sidered and with the growth potential predicted from Northern 
Europe it can be expected that these medicines will continue 
consuming an increasing share of Australian pharmaceutical 
expenditure in years to come. The 5 studied immunosuppres-
sants (mycophenolic acid, tacrolimus, cyclosporin, sirolimus, and 
everolimus) are high-cost, life-preserving drugs; increasing uti-
lization and expenditure have increased the financial impact 
felt by Australian and international pharmaceutical budgets.
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ATC code PBS item code Item description Qty Schedule Authority
L04AA06 8649F Mycophenolate mofetil 250 mg capsule 300 General Management of renal and cardiac 
allograft rejection8650G Mycophenolate mofetil 500 mg tablet 150
8651H Mycophenolate mofetil 1 g/5 mL oral liquid 
– 165 mL
1
6208R Mycophenolate mofetil 250 mg capsule 600 s100 HSD private
6209T Mycophenolate mofetil 500 mg tablet 300
6364Y Mycophenolate mofetil 1 g/5 mL oral liquid 
– 165 mL
2
9501C Mycophenolate mofetil 250 mg capsule 600 s100 HSD public Streamlined – 3355: management 
of renal rejection and 3356: 
cardiac rejection
9502D Mycophenolate mofetil 500 mg tablet 300
9500B Mycophenolate mofetil 1 g/5 mL oral liquid 
– 165 mL
2
*2150E Mycophenolate 180 mg tablet: enteric 120 General WHO Class III, IV or V lupus 
nephritis*2193K Mycophenolate 360 mg tablet: enteric 120
2150E Mycophenolate 180 mg tablet: enteric 120 Management of renal allograft 
rejection8653K Mycophenolate 360 mg tablet: enteric 120
6369F Mycophenolate 180 mg tablet: enteric 240 s100 HSD private Renal allograft rejection 
prophylaxis and WHO class III, IV 
or V lupus nephritis
6370G Mycophenolate 360 mg tablet: enteric 240
9503E Mycophenolate 180 mg tablet: enteric 240 s100 HSD public Streamlined – 4084: Prophylaxis 
of renal rejection and 4095: WHO 
Class III, IV or V lupus nephritis
9504F Mycophenolate 360 mg tablet: enteric 240
1836P Mycophenolate capsule 250 mg 300 General Management of renal and cardiac 
allograft rejection1837Q Mycophenolate capsule 250 mg 600 s100 HSD private
1839T Mycophenolate capsule 250 mg 600 s100 HSD public Streamlined – 3355: management 
of renal rejection and 3356: 
cardiac rejection
L04AD02 8646C Tacrolimus 0.5 mg capsule 100 General Maintenance of allograft rejection
8647D Tacrolimus 1 mg capsule 200
8648E Tacrolimus 5 mg capsule 200
6328C Tacrolimus 0.5 mg capsule 100 s100 HSD private Initiation and maintenance of 
allograft rejection6216E Tacrolimus 1 mg Capsule 200
6217F Tacrolimus 5 mg capsule 200
9558C Tacrolimus 0.5 mg capsule 50 s100 HSD public Streamlined: 3328 – management 
of allograft rejection9560E Tacrolimus 1 mg capsule 100
9561F Tacrolimus 5 mg capsule 100
5299X Tacrolimus 0.5 mg XR capsule 30 General Maintenance of allograft rejection
5300Y Tacrolimus 1 mg XR capsule 60
5451X Tacrolimus 5 mg XR capsule 60
9681M Tacrolimus 0.5 mg XR capsule 60 s100 HSD private Initiation and maintenance of 
allograft rejection9682N Tacrolimus 1 mg XR capsule 120
9683P Tacrolimus 5 mg XR capsule 120
9664P Tacrolimus 0.5 mg XR capsule 30 s100 HSD public Streamlined: 3328 – management 
of allograft rejection9665Q Tacrolimus 1 mg XR capsule 60
9666R Tacrolimus 5 mg XR capsule 60
Appendix 1. ATC codes and PBS item codes for immunosuppressants in Australia.
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Appendix 1 continued. ATC codes and PBS item codes for immunosuppressants in Australia.
ATC code PBS item code Item description Qty Schedule Authority
L04AD01 8657P Cyclosporin 10 mg capsule 120 General Organ rejection, atopic dermatitis, 
psoriasis, nephrotic syndrome and 
severe active RA
8658Q Cyclosporin 25 mg capsule 60
8659R Cyclosporin 50 mg capsule 60
8660T Cyclosporin 100 mg capsule 60
8661W Cyclosporin 100 mg/mL suspension 2
6232B Cyclosporin 10 mg capsule 120 s100 HSD private
6352H Cyclosporin 25 mg capsule 120
6353J Cyclosporin 50 mg capsule 120
6354K Cyclosporin 100 mg capsule 120
6125J Cyclosporin 100 mg/mL suspension 4
5632K Cyclosporin 10 mg capsule 120 s100 HSD public Streamlined: 3328 – organ 
rejection, 3329 –atopic dermatitis, 
3330 – psoriasis, 3331 – nephrotic 
syndrome & 3332 – severe active 
RA
5634M Cyclosporin 25 mg capsule 120
5635N Cyclosporin 50 mg capsule 120
5636P Cyclosporin 100 mg capsule 120
5633L Cyclosporin 100 mg/mL suspension 4
L04AA10 8984W Sirolimus 0.5 mg tablets 100 General Management of renal allograft 
rejection
8724E Sirolimus 1 mg tablets 100
8833X Sirolimus 2 mg tablets 100
8725F Sirolimus 1 mg/mL suspension 1
9748C Sirolimus 0.5 mg tablets 200 s100 HSD private
6436R Sirolimus 1 mg tablets 200
6457W Sirolimus 2 mg tablets 200
6437T Sirolimus 1 mg/mL suspension 2
9747B Sirolimus 0.5 mg tablets 200 s100 HSD public Streamlined: 3355 – management 
of renal allograft rejection
9549N Sirolimus 1 mg tablets 200
9548M Sirolimus 2 mg tablets 200
9550P Sirolimus 1 mg/mL suspension 2
L04AA18 8840G Everolimus 0.25 mg tablet 60 General Maintenance therapy following 
initation and stablisation in renal 
and cardiac transplant patients
8841H Everolimus 0.5mg tablet 60
8842J Everolimus 0.75mg tablet 120
9352F Everolimus 1 mg tablet 120
6459Y Everolimus 0.25 mg tablet 120 s100 HSD private Management of renal and cardiac 
allograft rejection
6460B Everolimus 0.5 mg tablet 120
6461C Everolimus 0.75 mg tablet 240
9582H Everolimus 1 mg tablet 240
5738B Everolimus 0.25 mg tablet 120 s100 HSD public Streamlined authority – 3355: 
Management of renal allograft 
rejection and 3356: Management 
of cardiac allograft rejection
5739C Everolimus 0.5 mg tablet 120
5740D Everolimus 0.75 mg tablet 240
5737Y Everolimus 1 mg tablet 240
* Data pertaining to utilisation of mycophenolic acid in lupus nephritis was collected for purposes of sensitivity analysis only.
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